Objective To investigate the effect of Furongtongmai capsule on the in-stent restenosis （ISR） of superficial femoral artery after interventional operation in lower extremity Arteriosclerosis Occlusion （ASO）....Objective To investigate the effect of Furongtongmai capsule on the in-stent restenosis （ISR） of superficial femoral artery after interventional operation in lower extremity Arteriosclerosis Occlusion （ASO）. Methods： A total of 110 inpatients with ASO who performed Superficial femoral artery stent implantation were randomly divided into observation group and control group, with 55 cases in each group.Both groups received Aspirin 100 mg/d and Clopidogrel 75 mg/d. The observation group was given Furongtongmai capsule on the basis of routine treatment. After continuous treatment for 6 months, the clinical efficacy, Ankle Brachial Index （ABI）, high-sensitivity C-reactive protein （Hs-CPR） and ISR were compared between the two groups. Results： At 6 months after operation, the plasma levels of Hs-CRP in the two groups were significantly lower than those in the control group （P 〈 0.05）. The ABI of treatment group was significantly higher than the control group （P 〈 0.05）. There was a statistically significant difference in ISR incidence between the treatment group and the control group 6 months after surgery （9.09% vs 27.78%, P 〈 0.05）. Conclusion： Furongtongmai Capsule can inhibit Hs-CRP in patients with ASO after femoral artery intervention, improve the ankle brachial index and reduce the incidence of ISR.展开更多
文摘Objective To investigate the effect of Furongtongmai capsule on the in-stent restenosis （ISR） of superficial femoral artery after interventional operation in lower extremity Arteriosclerosis Occlusion （ASO）. Methods： A total of 110 inpatients with ASO who performed Superficial femoral artery stent implantation were randomly divided into observation group and control group, with 55 cases in each group.Both groups received Aspirin 100 mg/d and Clopidogrel 75 mg/d. The observation group was given Furongtongmai capsule on the basis of routine treatment. After continuous treatment for 6 months, the clinical efficacy, Ankle Brachial Index （ABI）, high-sensitivity C-reactive protein （Hs-CPR） and ISR were compared between the two groups. Results： At 6 months after operation, the plasma levels of Hs-CRP in the two groups were significantly lower than those in the control group （P 〈 0.05）. The ABI of treatment group was significantly higher than the control group （P 〈 0.05）. There was a statistically significant difference in ISR incidence between the treatment group and the control group 6 months after surgery （9.09% vs 27.78%, P 〈 0.05）. Conclusion： Furongtongmai Capsule can inhibit Hs-CRP in patients with ASO after femoral artery intervention, improve the ankle brachial index and reduce the incidence of ISR.
